Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's accretion (amortization) of discounts and premiums, investments?
Bicara Therapeutics (BCAX) reported accretion (amortization) of discounts and premiums, investments of -$338K in Q1 2026.
What does accretion (amortization) of discounts and premiums, investments mean?
The periodic adjustment to the carrying value of investment securities to reflect the amortization of premiums or the accretion of discounts over the life of the instrument. This metric ensures that the interest income recognized aligns with the effective yield of the investment portfolio. It provides transparency into the accounting treatment of investment returns.